# Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

> **NCT02917096** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 18 (actual)

## Conditions studied

- Primary Myelofibrosis
- Secondary Myelofibrosis

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Fludarabine
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Melphalan
- **OTHER:** Pharmacological Study
- **DRUG:** Ruxolitinib
- **DRUG:** Ruxolitinib Phosphate
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT02917096
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-13
- **Primary completion:** 2020-04-16
- **Final completion:** 2023-08-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02917096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02917096, "Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT02917096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*